Alto Neuroscience (ANRO) Amortization of Deferred Charges (2023 - 2026)
Alto Neuroscience (ANRO) reported Amortization of Deferred Charges of $200000.0 for Q1 2026, up 5.26% on a YoY basis from $190000.0 in Q1 2025, and up 1.52% sequentially from $197000.0 in Q4 2025.
Alto Neuroscience (ANRO) Amortization of Deferred Charges (2023 - 2026) Analysis & Trends
Alto Neuroscience (ANRO) has 4 years of Amortization of Deferred Charges data on file, last reported at $200000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges rose 5.26% year-over-year to $200000.0; the trailing twelve-month figure through Mar 2026 stood at $784000.0 (up 72.31% YoY), and the FY2025 full-year result was $774000.0, up 129.67% from the prior year.
- Amortization of Deferred Charges rose to $200000.0 in Q1 2026, from $197000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $211000.0 in Q4 2024 to a low of $54000.0 in Q2 2024.
- A 4-year average of $132583.3 and a median of $132500.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges decreased 21.74% in 2024 and soared 255.56% in 2025, its largest moves.
- Tracing ANRO's Amortization of Deferred Charges over 4 years: stood at $71000.0 in 2023, then soared by 197.18% to $211000.0 in 2024, then decreased by 6.64% to $197000.0 in 2025, then gained by 1.52% to $200000.0 in 2026.
- Business Quant data shows ANRO's Amortization of Deferred Charges at $200000.0 in Q1 2026, $197000.0 in Q4 2025, and $195000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alto Neuroscience | 881.86 Mn | 881.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 197,000.00 |
| Dec 31, 2025 | 197,000.00 |
| Sep 30, 2025 | 195,000.00 |
| Sep 30, 2025 | 195,000.00 |
| Jun 30, 2025 | 192,000.00 |
| Jun 30, 2025 | 192,000.00 |
| Mar 31, 2025 | 190,000.00 |
| Mar 31, 2025 | 190,000.00 |
| Dec 31, 2024 | 211,000.00 |
| Dec 31, 2024 | 211,000.00 |
| Jun 30, 2024 | 54,000.00 |
| Jun 30, 2024 | 54,000.00 |
| Mar 31, 2024 | 72,000.00 |
| Mar 31, 2024 | 72,000.00 |
| Dec 31, 2023 | 71,000.00 |
| Dec 31, 2023 | 71,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Sep 30, 2023 | 65,000.00 |